An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)
|ClinicalTrials.gov Identifier: NCT00589901|
Recruitment Status : Unknown
Verified April 2008 by Fudan University.
Recruitment status was: Recruiting
First Posted : January 10, 2008
Last Update Posted : April 18, 2008
Information provided by:
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||December 2008|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
|1||February 11, 2010||February 26, 2010|
|2||May 25, 2010||June 18, 2010|
|3||July 9, 2010||August 9, 2010|
|4||March 16, 2011||April 15, 2011|
|5||July 1, 2011||July 29, 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, Hu X. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol. 2012 Feb;69(2):515-22. doi: 10.1007/s00280-011-1728-3. Epub 2011 Aug 27.